• Kandivali West Mumbai 400067, India
  • 022 39167251
  • support@email.com
June 23, 2020

Govt orders Patanjali to stop advertising its COVID drug CORONIL until their claim is examined

by facelesscompliance in Compliance Law

Govt orders Patanjali to stop advertising its COVID drug CORONIL until their claim is examined

Baba Ramdev-run Patanjali Ayurved on Tuesday launched Coronil and Swasari, an Ayurvedic medicine, to help treat the novel coronavirus or Covid-19 infection on Tuesday at Patanjali Yogpeeth in Haridwar, Uttarakhand.

The ‘Coronil kit’ has three medicines including 2 in tablet form and one liquid. Coronil works on the respiratory system of the body as coronavirus affects the respiratory system due to which its patients lose ability to breathe resulting in death.

The ayurvedic ingredients in the Coronil improves the body’s internal immunity and fight other Corona symptoms including fever, cough, cold.

Coronil dosage?

The kit contains three medicines which comprise of Coronil are — Andu Oil which has to be poured in nostrils (3-5 drops), two medicines in tablet form with 3 tablets for 3 times in a day for each of the two types of tablets.

When will it be available?

This will be available in 8 to 10 days.

Coronil kit price?

The Ayurvedic medicine has been launched today itself and its price is priced at ₹545. The corona kit is for 30 days.

Baba Ramdev said that their clinical trial found that 69% of the patients tested recovered from COVID-19 within three days, while 100% of the patients recovered within a week. Ramdev even claimed that 69 per cent of them recovered within 3 days. Balkrishna had earlier this month claimed that an Ayurvedic medicine developed by the company has been able to cure COVID-19 patients within 5-14 days. “We appointed a team of scientists after COVID-19 outbreak,” said Balkrishna, Ramdev’s close aide and MD of Patanjali Ayurved. He added that Patanjali conducted a clinical case study on hundreds of positive patients. Apart from Patanjali, in India, drugs like Dexamethasone, Remdesivir, Fabiflu, and Hydroxychloroquine are some of the known drugs that doctors are using in the treatment of coronavirus patients. With an increase of 14,821 new cases and 445 deaths, India’s COVID-19 count crossed 4.25 lakh on Monday. The country has reported a total of 4,25,282 cases and 13,699 persons have died.

Statement issued by the Ministry of Ayush on claims of Patanjali Ayurved regarding treatment of COVID-19

Ministry of AYUSH has taken cognizance of the news being recently flashed in the media about Ayurvedic medicines developed for treatment of COVID-19 by Patanjali Ayurved Ltd, Haridwar (Uttrakhand). Facts of the claim and details of the stated scientific study are not known to the Ministry.

The concerned Ayurvedic drug manufacturing company has been informed that such advertisements of drugs including Ayurvedic medicines are regulated under the provisions of Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and Rules thereunder and the directives issued by the Central Government in the wake of COVID outbreak. Ministry had also issued a Gazette Notification No. L.11011/8/2020/AS dated 21st April, 2020 stating the requirements and the manner the research studies on COVID-19 with Ayush interventions/medicines should be undertaken. 

In order to make this Ministry aware of the facts of the aforesaid news and verify the claims,  Patanjali Ayurved Ltd has been asked to provide at the earliest details of the name and composition of the medicines being claimed for COVID treatment; site(s)/hospital(s), where the research study was conducted for COVID-19; protocol, sample size, Institutional Ethics Committee clearance, CTRI registration  and results data of the study (ies) and stop advertising/publicizing such claims till the issue is duly examined. Ministry has also requested concerned State Licensing Authority of Uttrakhand Government to provide copies of license and product approval details of the Ayurvedic medicines being claimed for the treatment of COVID -19.

Enter your email address:

Subscribe to faceless complainces